· Executive Brief
National Surgical Oncologist Day 2026
A practical executive framework for access, ownership, handoffs, measurement, and improvement.
Leadership signal
National Surgical Oncologist Day can serve as an executive operating checkpoint.
Awareness can generate questions and requests for help. Executive teams can prepare by clarifying the first point of contact, the qualified team that accepts the request, the handoff standard, and the method used to verify completion without assuming that one route fits every person.
Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.
Executive opening
Surgical oncology is a coordination business as much as an operating room business
A cancer operation is the most visible moment in a long chain of decisions. Before it come diagnosis, staging, tumor board review, preparation and scheduling. After it come recovery, pain management, pathology review and the next phase of treatment. Most of the risk executives can manage sits in those handoffs rather than in the incision itself.
Delay is the clearest example. In an Arkansas cohort of 6,279 women whose first treatment for breast cancer was surgery, 12% had surgery more than 60 days after diagnosis.[1] Non-Hispanic Black patients had 82% higher odds of delay than non-Hispanic White patients.[1] Those numbers describe a pathway problem that no single surgeon can fix alone.
Coordination also changes what happens inside the pathway. At one tertiary referral center, pancreatic cancer patients presented at a multidisciplinary tumor board were more likely to receive appropriate workup before therapy, at 81.9% compared with 37.5%.[4] They also had fewer postoperative complications, at 30.7% compared with 58.3%.[4] The comparison is observational, but it shows why the tumor board is an operating asset worth governing.
Geography is the third pressure. Rural Medicare patients who had colon or lung cancer surgery at local rural hospitals had mortality and complication rates comparable to those treated at urban facilities.[2] Patients treated at urban facilities for colon cancer traveled 49 miles compared with 16 miles.[2] Regional strategy should therefore match each procedure to the right site rather than assume that every case must travel.
This section adds the evidence base beneath the operating guidance already on this page. It covers burden, the continuum of care, access, equity, workforce and communication, with each claim tied to a published study. The goal is to help executive teams decide which surgical oncology handoff to strengthen first. It also points to the decisions that belong with executives rather than individual clinicians.
Current evidence
What the research says about delay, tumor boards and outcomes
Time to surgery is measurable, and the evidence shows it varies by more than clinical need. In the Arkansas breast cancer cohort, residing in counties with high social vulnerability scores for housing and transportation was associated with greater odds of delay (adjusted odds ratio 1.38).[1] Higher county-level rates of routine doctor visits were associated with lower odds of delay (adjusted odds ratio 0.89).[1] The authors called for strengthened support services and improved continuity of care for vulnerable populations.[1]
Tumor board review is near-universal in some programs and still uneven in others. In the pancreatic cancer study, 166 of 190 patients (87.4%) were presented at the multidisciplinary tumor board.[4] The authors concluded that all patients diagnosed with pancreatic cancer should be discussed at these meetings.[4] For executives, the operating question is what happens to the patients who are not presented and why they were missed. Tracking that gap each month is a simple governance measure that most cancer committees can adopt.
Tumor boards can also add time. A single-center study included 572 patients with oropharyngeal cancer treated from 2010 to 2020.[5] Mean time to treatment initiation was 36.8 days for patients presented at a tumor board and 25.9 days for those who were not.[5] Five-year survival and disease-free survival did not differ between the groups.[5] The authors described both beneficial and negative effects of tumor board presentation, which makes meeting cadence and preparation a legitimate management concern.[5]
Real-world data from thoracic oncology show how tumor board decisions can be tracked to outcomes. A thoracic oncology board recommended neoadjuvant therapy for 275 of 769 patients (35.8%).[6] Disease progression during that therapy occurred in 8 patients (2.9%), and curative-intent resection was achieved in 246 (89.5%).[6] Treatment-related mortality was 1.1% during neoadjuvant therapy, compared with 5.3% after definitive chemoradiotherapy, and overall surgical mortality was 0.4%.[6] Among stage III patients, five-year overall survival was 69.0% in the neoadjuvant surgery group and 20.0% in the non-surgical group, though those groups were selected differently.[6]
Taken together, these studies show that coordination structures influence workup, timing and selection, yet each was conducted at a single center.[4][5][6] Local measurement is therefore essential before any program claims the same results. The most useful local data link each tumor board decision to the treatment actually delivered and the outcome that followed.
Figure 1
Coordination gaps show up in workup, complications, delay and recovery
Percent of patients in each study, as reported in that study. Values are copied from the cited studies [1], [4], [10]; none is estimated.
Data note. These values come from different studies, cancers, settings and periods, so this is an indirect comparison; only the three tumor board bars share one center, and that comparison is observational.
Limitation. Each value reflects its own denominator and definitions; the tumor board study included few patients who were not presented, and the opioid figure is self-reported.
Figure data (5 rows)
| Measure | Value | Population, setting and year as reported | Source |
|---|---|---|---|
| Appropriate pretherapy workup, presented at tumor board | 81.9% | Pancreatic cancer patients presented at a multidisciplinary tumor board, one tertiary referral center, 2019 to 2022 | [4] |
| Appropriate pretherapy workup, not presented | 37.5% | Patients at the same center who were not presented | [4] |
| Postoperative complications, not presented at tumor board | 58.3% | Same center and period; compared with 30.7% among patients presented | [4] |
| Continued opioid use beyond seven days after discharge | 42% | 107 opioid-naive patients after curative-intent elective cancer surgery, one center, 2021 to 2023 | [10] |
| Breast cancer surgery more than 60 days after diagnosis | 12% | 6,279 Arkansas women with first-line surgical treatment, 2013 to 2019 | [1] |
Continuum of care
From referral to recovery: the handoffs that carry the risk
Preparation before surgery is a distinct service line, even when it is not organized as one. One hospital applied a blood augmentation protocol to Jehovah’s Witness patients with anemia preparing for transfusion-free gastrointestinal or hepato-biliary-pancreatic cancer surgery.[11] Among 100 analyzed patients, 30-day mortality was 0% in both the anemic and non-anemic groups.[11] Median waiting time to surgery was 27 days in the anemic group receiving the protocol and 20 days in the non-anemic group, a difference that was not statistically significant.[11]
That study matters beyond its specific population. It shows that a structured, multidisciplinary preparation pathway can be run within the normal time to surgery.[11] In the anemic group, hemoglobin improved from 10.8 to 11.5 g/dL before surgery.[11] Prehabilitation programs of any kind need the same discipline: a trigger, an owner, a timeline and a measure of whether patients arrived better prepared.
The transition home is the next exposure point. In a prospective cohort of 107 opioid-naive patients after curative-intent elective cancer surgery, 42% continued opioid use beyond seven days after discharge.[10] Opioid use in the final 24 hours before discharge was described as a practical signal for risk stratification and individualized stewardship.[10] That is a discharge-planning measure, not only a prescribing one. Patients who continued opioids had higher pain interference and more opioid-related adverse events.[10]
Program design can also widen the continuum to include research and survivorship. A multidisciplinary meningioma program combined a weekly tumor board, a multidisciplinary clinic, prospective registries and a support group.[7] In its first 15 months, 602 cases were discussed at its tumor board and 142 patients were seen in the multidisciplinary clinic.[7] Twelve percent of patients discussed were offered clinical trial enrollment, and 84% were offered prospective registry enrollment.[7] After implementation, consultation volume for meningioma rose by 87.0% to 533.3%, and treatment volume rose by 42.1% to 115.2% across clinical departments.[7]
Executives should see these examples as one continuum with several owners. Preparation, decision, operation, discharge and follow-up are often managed by different departments with different metrics. Without a shared view, a delay or a missed signal in one segment shows up later as a complication or readmission in another. A single pathway owner with cross-department data can see those links before they become harm.
Figure 3
Why the pathway breaks
People
- Coordinator and navigator time not budgeted to the service line
- Training models misaligned with clinical practice needs
- Rural surgeons covering broad scope without specialist backup
Process
- Some patients never presented at a tumor board
- Tumor board cadence adding days to treatment start
- No standard preparation pathway before surgery
Technology
- Incomplete tumor board documentation
- Decision-support tools used without subgroup checks
- Patient-facing explanations that are hard to understand
Environment
- Long travel distances to urban centers
- Housing and transportation vulnerability
- Few regions meeting surgeon-to-population guidelines
Policy
- Payment models that shift volume unevenly by cancer type
- No published rules for which procedures go to which sites
- Opioid stewardship not built into discharge planning
Measurement
- Time to surgery not stratified by race or community vulnerability
- Tumor board decisions not linked to outcomes
- Post-discharge opioid use and complications not tracked
Unranked qualitative cause-and-effect diagram for the outcome in the box: Cancer surgery patients experience avoidable delay, incomplete workup, complications or poorly supported recovery Causes are assembled from the cited literature [1], [2], [3], [4], [5], [6], [8], [9], [10], [11], [12], [14], [15]; categories are not weighted and their order carries no meaning.
Data note. Qualitative; no frequencies are implied.
Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.
Figure data (6 rows)
| Category | Causes drawn from the cited literature |
|---|---|
| People | Coordinator and navigator time not budgeted to the service line; Training models misaligned with clinical practice needs; Rural surgeons covering broad scope without specialist backup |
| Process | Some patients never presented at a tumor board; Tumor board cadence adding days to treatment start; No standard preparation pathway before surgery |
| Technology | Incomplete tumor board documentation; Decision-support tools used without subgroup checks; Patient-facing explanations that are hard to understand |
| Environment | Long travel distances to urban centers; Housing and transportation vulnerability; Few regions meeting surgeon-to-population guidelines |
| Policy | Payment models that shift volume unevenly by cancer type; No published rules for which procedures go to which sites; Opioid stewardship not built into discharge planning |
| Measurement | Time to surgery not stratified by race or community vulnerability; Tumor board decisions not linked to outcomes; Post-discharge opioid use and complications not tracked |
Access
Access depends on matching procedures to the right sites
Centralization and local access are often framed as opposites, but the evidence suggests a more selective approach. The rural surgery study identified 10,383 rural patients with colon cancer and 6,006 with lung cancer who had elective surgery.[2] Comparable short-term outcomes at local rural facilities meant patients could avoid the travel burden of treatment at higher-volume urban facilities.[2] That finding applies to common procedures, not to every complex operation. Travel avoided is time, cost and caregiver burden that patients do not have to absorb.
Payment models influence where surgery happens. The Pennsylvania Rural Health Model used all-payer hospital global budgets, and researchers examined 22,728 cancer surgeries across 60 hospital service areas.[3] Pooled estimates showed no statistically significant differential changes in where patients had surgery or how far they traveled.[3] In areas served by smaller and more remote participating hospitals, surgery at accredited cancer hospitals showed a differential increase of 8.7 percentage points.[3]
The same model was associated with decreases in surgery at accredited and high-volume hospitals for liver cancer.[3] That mixed pattern shows why access strategy has to be procedure-specific. A financial incentive that helps one cancer type reach accredited care may move another in the opposite direction. Surgery at National Cancer Institute centers for bladder cancer also decreased in that analysis.[3] Leaders evaluating new payment arrangements should monitor site of surgery by cancer type, not only in aggregate.
Rural access also depends on the surgeons themselves. A narrative review examined rural surgical units in Western Australia, noting that 29% of Australians live rurally.[14] Rural general surgeons there manage higher procedural volumes per surgeon and a broader scope of practice than metropolitan peers.[14] It reported disparities in surgical oncology and trauma mortality linked largely to access and transport times.[14] Workforce shortages left few regions meeting surgeon-to-population guidelines and increased reliance on fly-in-fly-out services.[14]
For health system leaders, the practical lesson is to define which procedures belong at which sites and to publish those referral rules. Patients and referring clinicians should know where a case will go, how quickly it will be seen and who coordinates travel when centralization is the right answer. Access that depends on informal relationships is fragile and hard to measure. Referral rules should also say when a rural case is escalated and who accepts it at the receiving center.
Executive guidance · System route
Build one visible operating route for National Surgical Oncologist Day.
Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.
The route at a glance
- Listen
- Clarify entry
- Coordinate the partner route
- Protect transitions
- Verify and learn
Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.
Listen
Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions.
Clarify entry
Publish a plain-language first step and identify who receives requests through each approved channel.
Coordinate the partner route
Align internal teams and external partners around one current message, real entry point, receiving owner, escalation path, and follow-through signal.
Protect transitions
Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations.
Verify and learn
Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals.
Figure 2
The system route as one flow
The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.
Data note. Shows sequence and handoffs only; it carries no counts or rates.
Limitation. Local processes may add, merge or reorder stages under organizational policy.
Figure data (5 rows)
| Stage | What the stage requires |
|---|---|
| Listen | Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions. |
| Clarify entry | Publish a plain-language first step and identify who receives requests through each approved channel. |
| Coordinate the partner route | Align internal teams and external partners around one current message, real entry point, receiving owner, escalation path, and follow-through signal. |
| Protect transitions | Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations. |
| Verify and learn | Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals. |
Equity and trust
Equity: delay is not evenly distributed
The breast cancer delay study is one of the clearest recent signals for equity work in surgical oncology. Non-Hispanic Black patients had an adjusted odds ratio of 1.82 for surgery after 60 days compared with non-Hispanic White patients.[1] The authors concluded that disparities in delay persist across race, healthcare access and community-level vulnerability.[1] Overall, 12% of patients in that cohort waited longer than 60 days, so the disparity sits inside a broader delay problem.[1]
Community conditions sit alongside individual characteristics. Housing and transportation vulnerability at the county level was associated with greater odds of delay, while higher rates of routine doctor visits were associated with lower odds.[1] That pattern points toward navigation, transportation support and primary care connection as levers health systems can influence. It also suggests stratifying time-to-surgery data by community vulnerability, not only by race. Programs that already run navigation can test whether transport support shortens time to surgery for patients in high-vulnerability counties.
Rural residence is its own equity dimension. The Western Australian review linked disparities in surgical oncology mortality to access issues and transport times.[14] It also identified research gaps in specific surgical oncology outcomes for rural populations.[14] Health systems serving rural regions should treat travel distance and transport time as measured variables, not background facts. Distance, road access and transport availability can be recorded for each referral.
Equity also applies to who makes decisions about care. Analysis of the Society of Surgical Oncology found that women made up 49.3% of committee members in 2024, up from 25.5% in 2010.[13] The authors attributed the change to broader societal advances toward inclusivity and the society’s efforts to promote career development.[13] Diverse decision-making bodies matter for trust, especially when tumor boards decide which patients are offered surgery. Representation data for local surgical departments and tumor boards can be reviewed in the same way.
Technology can widen or narrow these gaps. In a study comparing tumor board decisions with AI-generated recommendations, discordance was more frequent among male patients (5 of 19, 26.3%) than female patients (2 of 28, 7.1%).[9] The sample of 47 patients is small, but the result is a reminder to check any decision-support tool for subgroup differences before it informs care.[9] Equity review should therefore cover tools as well as people and processes.
Human infrastructure
Human infrastructure: training the surgeons the system actually needs
The surgical oncology workforce is shaped long before a surgeon joins a health system. A study of 483 complex general surgical oncology fellowship graduates from 20 U.S. programs examined their careers after training.[15] Although 71% completed dedicated research time during residency, only 9% received extramural funding, and 60% had an m-index lower than 1.[15] Survey responses came from 181 graduates.[15]
Most graduates surveyed devoted the majority of their careers to clinical work and supported restructuring training to match actual practice.[15] The authors called for clinically focused and research-intensive fellowship tracks that better align with trainee goals and workforce needs.[15] For health systems recruiting surgical oncologists, that misalignment means clinical leadership, operational skill and teamwork deserve explicit weight in hiring. Recruitment interviews and onboarding plans can test for those capabilities directly.
Rural workforce gaps compound the problem. The Western Australian review described rural general surgeons covering endoscopy and procedures outside traditional general surgery, such as plastics, urology and vascular work.[14] It concluded that training requires a generalist focus with specialist exposure and non-technical skills development.[14] Networks that rely on rural generalists need structured links to specialist colleagues for complex cancer cases. The review also noted that unplanned returns to theater in rural Western Australia are largely unquantified.[14] Without such measures, leaders cannot tell whether broad rural scope is safe for each procedure type.
Tumor boards are also a workforce cost. Documentation of multidisciplinary discussion is complex, and a prospective quality improvement study evaluated ambient AI for head and neck tumor board notes across 12 tumor boards.[8] Prompt-directed ambient AI improved total documentation scores without increasing per-patient discussion time.[8] Compared with manual documentation, ambient AI improved documentation quality while diminishing administrative burden.[8] The study compared four cohorts: unprompted ambient AI, prompt-directed ambient AI, manual documentation and internal validation.[8]
Workforce planning should count that coordination time. Navigators, coordinators, pathologists, radiologists and anesthesiologists all contribute to each tumor board decision, yet their time is rarely budgeted as part of the surgical service line. Leaders who measure only operating room minutes will underestimate the real staffing needed to deliver timely, well-coordinated cancer surgery. Budgeting that time openly makes it easier to protect when operating room demand rises. Coordination roles also need clear escalation paths when a case stalls between specialties.
Executive guidance · Operating dashboard
Use a small dashboard to expose friction and ownership.
Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.
Four operating signals
Each signal pairs an executive question with one candidate local measure, set out below.
Executive guidance · Signal
Entry-point clarity
Can people and staff identify the approved first step without searching across conflicting instructions?
- Candidate local measure
- Locally defined contact, routing, and repeat-contact signals by channel and service.
Executive guidance · Signal
Ownership reliability
Does a specific team accept each request and make its status visible?
- Candidate local measure
- Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
Executive guidance · Signal
Partner-route reliability
Do participating teams share one current route and understand who owns each dependency?
- Candidate local measure
- Locally defined conflicting instructions, unaccepted handoffs, unresolved dependencies, repeat contacts, and partner feedback.
Executive guidance · Signal
Improvement closure
Does the organization correct recurring friction and report what changed?
- Candidate local measure
- Selected barriers, assigned actions, completion status, and post-change review.
Figure 4
The operating system behind the dashboard
The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.
Data note. Structural diagram; no measured values.
Limitation. Owners are candidates to be confirmed locally.
Figure data (4 rows)
| Operating signal | Candidate owner |
|---|---|
| Entry-point clarity | Executive sponsor and operational lead |
| Ownership reliability | Operational owner and participating teams |
| Partner-route reliability | Sending and receiving owners |
| Improvement closure | Improvement owner and executive sponsor |
Executive guidance · Handoff workflow
Close the loop across teams, settings, and partners.
A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.
How responsibility moves
Lane A
From message to accepted ownership
- Confirm the approved message and intended audience.
- Publish the actual entry point and receiving role.
- Acknowledge receipt using the locally approved method.
- Escalate when ownership or response remains unclear.
Lane B
From accepted ownership to verified follow-through
- Record the next accountable owner and visible status.
- Name the sending and receiving owners, shared information, current status, and unresolved dependency.
- Keep unresolved work visible across boundaries.
- Confirm closure or document the continuing exception.
Executive guidance · Executive scorecard
Give leaders one view of route reliability and improvement.
The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.
Who reviews what
- Executive sponsor and operational lead
- Operational owner and participating teams
- Sending and receiving owners
- Improvement owner and executive sponsor
Candidate owners named in the scorecard, confirmed locally.
| Operating signal | Executive question | Candidate owner | Suggested review point |
|---|---|---|---|
| Entry-point clarity | Can people and staff identify the approved first step without searching across conflicting instructions? | Executive sponsor and operational lead | At campaign launch and close |
| Ownership reliability | Does a specific team accept each request and make its status visible? | Operational owner and participating teams | At a locally defined cadence |
| Partner-route reliability | Do participating teams share one current route and understand who owns each dependency? | Sending and receiving owners | At a locally defined cadence |
| Improvement closure | Does the organization correct recurring friction and report what changed? | Improvement owner and executive sponsor | Until action is verified |
Figure 5
Control points for a reliable surgical oncology pathway
| Control point | Risk if missing | Owner | Evidence of control |
|---|---|---|---|
| Defined time-to-surgery standard with stratified reporting | Delays concentrate among Black patients and vulnerable communities without anyone noticing | Cancer service line executive with quality lead | Share of patients meeting the standard, by race, insurance and community vulnerability |
| Tumor board presentation rule for each cancer type | Patients miss complete workup and multidisciplinary review | Cancer committee chair | Share of eligible patients presented before definitive treatment |
| Tumor board scheduling and preparation standard | Review adds avoidable days to treatment start | Tumor board coordinator and physician lead | Days from referral to tumor board decision |
| Published site-of-care rules for common and complex procedures | Unnecessary travel or care at low-volume sites for complex cases | Chief medical officer and regional network leaders | Annual review of procedure location and outcomes by site |
| Structured preparation pathway before surgery | Patients arrive anemic or unprepared, or surgery is delayed | Perioperative medicine and anesthesiology leaders | Share of eligible patients completing preparation within the scheduled interval |
| Discharge opioid stewardship signal | Prolonged opioid use after discharge goes unaddressed | Surgical pharmacy and nursing leaders | Share of patients with day-seven follow-up on opioid use |
| Governance review for AI and ambient documentation tools | Tools introduce subgroup bias or inaccurate records | Chief medical information officer and ethics committee | Documented validation, subgroup check and audit before use |
Control points derived from the cited evidence [1], [2], [4], [5], [8], [9], [10], [11] and this brief’s executive guidance.
Data note. Each row is a control to verify, not a measured result.
Limitation. Owners and evidence of control must follow local policy and applicable requirements.
Public communication
Communication: shared understanding for patients and teams
Complex cancer surgery asks patients to understand anatomy, risk and sequencing at a stressful moment. A human-centered design study in hepato-pancreato-biliary surgical oncology involved 14 oncology professionals and 10 patients in co-design workshops and interviews.[12] The resulting augmented reality prototype achieved a mean System Usability Scale score of 67.25, indicating acceptable usability.[12] Ten hepatobiliary clinicians tested the prototype in simulated tumor board planning scenarios.[12]
Patients in the co-design phase valued engaging with their own anatomy in an emotionally manageable way.[12] They reported that interactive visualization improved their understanding and sense of agency.[12] Clinicians using the prototype in simulated tumor board scenarios reported improved spatial understanding and enhanced interdisciplinary communication.[12] Communication tools work best when they are designed with patients rather than delivered to them. Their feedback suggests that comprehension is an outcome worth measuring, not just a courtesy.
Team communication is equally important. In the general surgery AI study, full concordance with tumor board decisions occurred in 18 of 47 cases (38.3%), partial concordance in 22 (46.8%) and discordance in 7 (14.9%).[9] Discordance most often arose from resectability assessment and staging interpretation, and AI tended to favor broader surgical candidacy.[9] The authors concluded that AI may complement but not replace multidisciplinary judgment.[9] The divergence appeared at critical surgical decision points, which is where human review matters most.[9]
Clear records are part of trustworthy communication. Ambient documentation improved the quality of tumor board records in one study, and the next clinician depends on that record to explain the plan.[8] In the pancreatic cancer study, presentation at a tumor board was linked to more complete workup before therapy.[4] Leaders should ensure that tumor board decisions reach patients in plain language and within a defined time. Every plan shared with a patient should carry the tumor board date and the name of the coordinating clinician.
Public messaging for this observance should focus on what patients can expect from the system. That includes how quickly a case will be reviewed, who will coordinate preparation and travel and how decisions will be explained. Specific promises should match measured performance, so communication teams need the same time-to-surgery and tumor board data that operating leaders review. Patients and families also need a named contact for questions between the tumor board decision and the day of surgery.
Executive guidance · 90-day plan
Turn the observance into one sustained operating change.
The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.
Ninety days, three moves
- Days 1–30See the current route
- Days 31–60Build the reliable path
- Days 61–90Make the change visible
Days 1–30 · Listen and map
See the current route
- Name an executive sponsor and an operational owner.
- Listen to people using the route and representative frontline teams.
- Map how National Surgical Oncologist Day communications connect to real entry points, owners, transitions, and escalation.
- Select one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and test
Build the reliable path
- Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
- Validate the design with every sending and receiving team involved.
- Test one internal or partner handoff and correct a verified communication, dependency, or ownership gap.
- Test the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verify
Make the change visible
- Launch the redesigned route with a small set of locally defined measures.
- Review unresolved work and recurring friction using a learning approach.
- Correct implementation barriers and record who owns each remaining dependency.
- Report what changed, what evidence was reviewed, and what still requires live oversight.
Figure 6
The 90-day plan on one timeline
The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.
Data note. Time boxes are a management framework, not a clinical timeline.
Limitation. Durations are uniform 30-day windows; real tasks may span windows.
Figure data (12 rows)
| Window | Action |
|---|---|
| Days 1–30 · Listen and map | Name an executive sponsor and an operational owner. |
| Days 1–30 · Listen and map | Listen to people using the route and representative frontline teams. |
| Days 1–30 · Listen and map | Map how National Surgical Oncologist Day communications connect to real entry points, owners, transitions, and escalation. |
| Days 1–30 · Listen and map | Select one recurring barrier that the organization can responsibly address. |
| Days 31–60 · Design and test | Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal. |
| Days 31–60 · Design and test | Validate the design with every sending and receiving team involved. |
| Days 31–60 · Design and test | Test one internal or partner handoff and correct a verified communication, dependency, or ownership gap. |
| Days 31–60 · Design and test | Test the route in more than one representative setting or operating period where practical. |
| Days 61–90 · Implement and verify | Launch the redesigned route with a small set of locally defined measures. |
| Days 61–90 · Implement and verify | Review unresolved work and recurring friction using a learning approach. |
| Days 61–90 · Implement and verify | Correct implementation barriers and record who owns each remaining dependency. |
| Days 61–90 · Implement and verify | Report what changed, what evidence was reviewed, and what still requires live oversight. |
Executive guidance · Leadership close
Make National Surgical Oncologist Day a starting point, not an endpoint.
Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.
Leadership commitment
Make ownership visible, test the route, and report what improved.
Executive action kit · Day observance
Turn National Surgical Oncologist Day into accountable action.
A practical executive framework for access, ownership, handoffs, measurement, and improvement.
Leadership focus
Use this observance to examine trustworthy information, prevention access, and community connection. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.
Workforce lens
Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the information, access, coordination, and follow-through pathway.
Patient and community lens
Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.
Equity and access lens
Review language, disability, transportation, digital access, geography, trust, and other barriers using protected feedback and locally appropriate data.
Five-minute briefing
Inspect the operating sequence
Listen with people using the pathway, frontline teams, operational leaders, and community partners. Find one a message, request, referral, or handoff that does not reach an accountable owner, then test the locally approved route from entry through acknowledged follow-through.
- Listen
- Clarify entry
- Coordinate the partner route
- Protect transitions
- Verify and learn
Leadership actions for this week
- Name an executive sponsor and frontline operating owner.
- Ask people using and operating the pathway where ownership becomes unclear.
- Test one representative route from first question to acknowledged next step.
- Select one barrier that can be corrected without overstating the evidence.
- Set a review date and define how completion will be verified.
Candidate measures
Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.
- Locally defined contact, routing, and repeat-contact signals by channel and service.
- Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
- Locally defined conflicting instructions, unaccepted handoffs, unresolved dependencies, repeat contacts, and partner feedback.
Department readiness checklist
- The public and staff entry points match the actual approved process.
- A specific role accepts each request, referral, or escalation.
- Handoffs include acknowledgment and a visible unresolved state.
- Language, disability, digital, transportation, and trust barriers receive explicit review.
- Communications do not introduce unsupported themes, statistics, or clinical advice.
- A named leader will review what changed after the observance.
Intended audiences
- Executive and Operational Leaders
- Public Health and Community Partners
Staff communication template
During National Surgical Oncologist Day, our organization will connect awareness with a practical review of the information, access, coordination, and follow-through pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.
Community communication template
National Surgical Oncologist Day is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.
Measurement worksheet
- Signal
- What observable condition will show whether the route works?
- Definition
- What is included, excluded, and counted?
- Owner
- Who reviews the signal and acts on exceptions?
- Cadence
- When will leaders review it?
- Equity check
- Which differences require protected, locally appropriate review?
- Closure
- What evidence will confirm the improvement was completed?
- Editorial review
- Completed
- Source records
- 2 listed under Authoritative resources
- Review standard
- Sourced facts remain separated from original executive guidance
- Clinical boundary
- No new statistical or clinical claim was added by this action kit
Sources and content boundary
Authoritative resources
- Observance source: nationaldaycalendar.com
- 2026 healthcare observances calendar: nationaldaycalendar.com
Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.
Peer-reviewed references
References
Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .
- 1.Boyd M, Rezaeiahari M, Schootman M, Park YM, Owsley KM. Delay in breast cancer surgery: evaluating patient, healthcare access, and social vulnerability predictors. Cancer Causes & Control. 2026;37(3):49. https://doi.org/10.1007/s10552-026-02127-2
- 2.Egger ME, Jones T, Piamonte Q, Zhang CH, Karimi S, Little BB, et al. Perioperative Outcomes of Rural-Dwelling Patients Undergoing Lung and Colon Cancer Operations in Rural Facilities. Journal of the American College of Surgeons. 2026;242(4):1032-1038. https://doi.org/10.1097/xcs.0000000000001781
- 3.Sabik LM, Whitman J, Bourne DS, Sun Z, Roberts ET, Yabes JG, et al. Impacts of a Rural Hospital Global Budget Alternative Payment Model on Patterns of Cancer Surgery. Medical Care. 2026;64(8):492-499. https://doi.org/10.1097/mlr.0000000000002336
- 4.Breit C, Gibbs J, Sharma S, Obaid A, Kimbrough C, Preskitt J, et al. Management and outcomes of patients undergoing high-risk oncologic pancreatic surgery: do patients presented at pancreatic multidisciplinary tumor board fare better?. Baylor University Medical Center Proceedings. 2026;39(6):947-951. https://doi.org/10.1080/08998280.2026.2718630
- 5.Burkhardt V, El-Shabrawi K, Spörlein A, Schulz T, Riemann S, Becker C, et al. Multidisciplinary Tumor Board in Oropharyngeal Cancer: Impact on Treatment Regimen, Treatment Initiation and Survival. Clinical Oncology. 2026;59:104335. https://doi.org/10.1016/j.clon.2026.104335
- 6.Özer E, Melek H, Deligönül A, Bayram AS, Gebitekin C. Decision-to-outcome analysis of multidisciplinary tumor board-managed NSCLC patients. Turkish Journal of Thoracic and Cardiovascular Surgery. 2026. https://doi.org/10.4274/tjtcs.2026.2026-2-25
- 7.Arum Z, Morshed RA, Braman BC, Mirchia K, Villanueva-Meyer JE, Mouton V, et al. A multidisciplinary program for meningioma treatment, research, and support services. Neuro-Oncology Practice. 2026;13(5):918-927. https://doi.org/10.1093/nop/npag051
- 8.Philips R, Mahajan A, Estephan L, Auger S, Haque W, Palmer D, et al. Prompt-directed ambient artificial intelligence for automated multidisciplinary tumor board documentation. Annals of Oncology. 2026;37(10):1437-1449. https://doi.org/10.1016/j.annonc.2026.05.709
- 9.Zengin Deniz A, Ulfanov O, Angin YS, Demir M, Gundogdu E, Ulas M, et al. Multidisciplinary tumor board decisions and artificial intelligence-generated recommendations in general surgery: a retrospective observational study. Updates in Surgery. 2026. https://doi.org/10.1007/s13304-026-02749-w
- 10.Lee KKH, Yiu CH, Penm J, Johns A. The Patterns and Trajectory of Continued Opioid Use in Opioid-Naïve Patients After Curative-Intent Elective Cancer Surgery-A Prospective Cohort Study. Pain Practice. 2026;26(5):e70162. https://doi.org/10.1111/papr.70162
- 11.Miyaishi K, Kawamoto S, Yamamoto K, Tokushige A, Ueda S. Preoperative Blood Augmentation in Jehovah’s Witness Patients Undergoing Transfusion-Free Surgery for Gastrointestinal or Hepato-biliary-pancreatic Cancer: Retrospective Cohort Study. Anesthesia & Analgesia. 2026. https://doi.org/10.1213/ane.0000000000008160
- 12.Matsangidou M, Kowal MR, Yianni J, Krini M, Pathak S, Gordon K, et al. From Prototype to Practice: Mixed Methods Study of Human-Centered Design and Usability Evaluation of Augmented Reality for Complex Oncology Surgical Workflows. JMIR Human Factors. 2026;13:e86725-e86725. https://doi.org/10.2196/86725
- 13.Gaughan NA, Conroy MM, McLaughlin S, Jeruss JS, Hunt KK, Teshome M, et al. Closing the Gap: A Longitudinal Review of the Trends of Gender Representation in the Society of Surgical Oncology Membership and Annual Meetings. Annals of Surgical Oncology. 2026;33(8):7265-7271. https://doi.org/10.1245/s10434-026-19761-4
- 14.Heath DP, Kim K, Dilevska T, Pardhan A, Cover J. Case Mix Analysis in Rural Surgical Units in Western Australia: Identifying Research Gaps and Future Directions: A Narrative Review. ANZ Journal of Surgery. 2026:ans.70925. https://doi.org/10.1111/ans.70925
- 15.Whitham ZA, Hu E, Russell MC, Dineen S, Porembka MR, Zeh HJ, et al. Longitudinal Academic Productivity of Complex General Surgical Oncology Fellowship Graduates: Misalignment Between Training, Career Trajectory, and Workforce Needs. Annals of Surgical Oncology. 2025;33(1):29-38. https://doi.org/10.1245/s10434-025-18329-y
Claim-to-source matrix
What each source supports
Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.
| Claim group | Sources | Years | Used in | Limitation |
|---|---|---|---|---|
| Delay in breast cancer surgery and its social and access predictors | [1] | 2026 | Equity and trust | Arkansas registry and claims data from 2013 to 2019; women receiving surgery first; county-level measures may not reflect individual circumstances. |
| Outcomes of rural patients treated at rural versus urban facilities | [2] | 2026 | Access | Medicare-aged patients with stage I to III colon and lung cancer; short-term outcomes only; elective procedures. |
| Global budget payment model and patterns of cancer surgery | [3] | 2026 | Access | Pennsylvania model only; pooled effects were not significant and subgroup effects varied by cancer type. |
| Tumor board presentation, workup and complications in pancreatic cancer | [4] | 2026 | Current evidence | Single tertiary center retrospective review of 190 patients; small comparison group not presented. |
| Tumor board presentation and time to treatment in oropharyngeal cancer | [5] | 2026 | Current evidence | Single-center retrospective cohort from 2010 to 2020; groups were not randomized. |
| Decision-to-outcome tracking in a thoracic tumor board cohort | [6] | 2026 | Current evidence | Single-center retrospective cohort from 2015 to 2019; selected patients for neoadjuvant therapy. |
| Implementation of a multidisciplinary disease-specific program | [7] | 2026 | Continuum of care | One academic institution; early implementation results without a comparison group. |
| Ambient AI for tumor board documentation | [8] | 2026 | Human infrastructure | Quality improvement study of 12 head and neck tumor boards at one institution. |
| AI-generated recommendations compared with tumor board decisions | [9] | 2026 | Public communication | Retrospective study of 47 patients at one center; one AI model; small subgroup counts. |
| Continued opioid use after discharge from cancer surgery | [10] | 2026 | Continuum of care | Single-center prospective cohort of 107 opioid-naive patients in three specialties; self-reported use. |
| Structured preparation before cancer surgery | [11] | 2026 | Continuum of care | Retrospective single-hospital study of Jehovah’s Witness patients; findings may not generalize to other populations. |
| Patient and clinician co-design of communication tools | [12] | 2026 | Public communication | Small convenience samples and simulated scenarios; usability rather than clinical outcomes. |
| Surgical oncology workforce training, careers and representation | [13] [15] | 2026, 2025 | Human infrastructure | Professional society records and one cohort of U.S. fellowship graduates; survey response was partial. |
| Rural surgical workforce and access | [14] | 2026 | Access | Narrative review focused on Western Australia; draws partly on service reports and workforce data. |
About the author
Greg Wahlstrom
MBAHCM
President and Chief Executive Officer, The Healthcare Executive
View Greg’s profile©2014 – 2026 The Healthcare Executive. All rights reserved.